Mental illness represents a broad spectrum of health conditions affecting mood, thinking and behavior. These conditions include depression, bipolar disorder, schizophrenia, substance use disorder, anxiety disorders, eating disorders, obsessive compulsive disorder and post-traumatic stress disorder, among others. Each of these illnesses often varies in its degree of severity, ranging from mild to moderate to severe, and may occur together. In severe cases, mental illnesses can cause serious functional impairment and substantially interfere with or place limits on life activities –– these are considered serious mental illnesses (SMI). Regardless of severity, mental illness can often get in the way of one’s daily activities, personal and professional relationships and limit one’s quality of life.
Fortunately, hope is on the horizon as biopharmaceutical research companies have made tremendous strides towards understanding mental illnesses and developing innovative medicines. By leveraging a growing scientific understanding of the brain, biopharmaceutical researchers are seeking to develop new treatments and bring therapeutic advances for patients who are not helped by current standards of care or for those who may experience negative side effects.
Today, PhRMA released a new report covering 163 medicines in development that are targeting common mental illnesses, all of which are in clinical trials or awaiting review by the U.S. Food and Drug Administration (FDA). The promise of the pipeline is represented across a wide range of mental illnesses, including:
- 54 for depression, which affects 8.4% of adults and 17% of adolescents aged 12 to 17 in the U.S.
- 35 for schizophrenia, which affects less than 1% of U.S. adults.
- 35 for anxiety disorders. More than a third of adults in the U.S. report experiencing anxiety during their lifetime.
- 33 for substance use disorders. Over 40 million Americans ages 12 and older—or
- 14.5% of the U.S. population—reported having a substance use disorder in 2020.
- 13 for bipolar disorder which affects about 2.8% of adults and 2.9% of adolescents in the U.S.
- 8 for attention-deficit/hyperactivity disorder (ADHD) which is one the most common childhood disorders with a lifetime prevalence of 11.0% in children ages four to 17 and 8.7% in adolescents ages 13 to 18. ADHD also affects 4.4% of adults in the U.S.
While mental illnesses can impact anyone at any time, not everyone has adequate access to needed care. In fact, more than half of U.S. adults with a mental illness do not receive any treatment at all. Health care access insecurity for patients with mental illness is often driven by coverage and access restrictions. PhRMA’s recent Patient Experience Survey found that patients are increasingly experiencing barriers to adequate care despite having insurance. The survey found:
- 61% of insured Americans managing a mental health condition and taking prescription medicines are concerned the medicines they are prescribed will be subject to insurance formulary exclusion, compared to just 47% of insured Americans taking prescription medicines.
- 56% of insured Americans managing a mental health condition and taking prescription medicines are concerned they would have to wait for their insurer to provide prior authorization for a medicine their doctor prescribed, compared with 42% of insured Americans taking prescription medicines.
- 33% of insured Americans managing a mental health condition have difficulty understanding, anticipating and navigating their insurance coverage, compared with 22% of insured Americans overall.
- At the same time, 94% of insured Americans managing a mental health condition want more predictability in their out-of-pocket costs so that they know how much they will pay for things like prescription drugs every month.
The alarming pace by which rates of mental illness and addiction are increasing across the country demands a comprehensive and multifaceted strategy to stem the tide of these crises. Unfortunately, our health care system is not equipped to handle these increasing trends and ensure patients can access the care they need. In order to fully address the growing mental health challenge in the United States, additional policy reforms are needed that focus on the significant barriers to accessing quality care for patients with these devastating diseases. The biopharmaceutical industry supports policies to:
- Reduce the stigma of mental illness and substance use disorders and bolster our behavioral health workforce.
- Improve access to the comprehensive range of treatment services needed to successfully manage these conditions and make insurance work as intended.
- Greater enforcement of mental health parity laws.
- Leverage and expand the appropriate use of telehealth, while ensuring safeguards to protect the quality of patient care.
- Improve care coordination and delivery through new quality care models
America’s biopharmaceutical research companies are committed to addressing the stigma of mental illness and researching and developing medicines to improve the health and wellbeing of those struggling with these illnesses. The medicines in development today represent the continued commitment of our industry to advance new treatment options for a wide range of mental illnesses and the diverse patient populations impacted by them.
Read the full report here.
Matthew Norawong
Matthew is a senior manager on PhRMA’s Public Affairs team focusing on Medicare, Medicaid, importation and more. Prior to coming to PhRMA, he previously worked as a health policy analyst for National Journal’s Network Science Initiative, primarily supporting companies in the life sciences industry. Matthew completed his undergraduate studies in political science at the University of Washington and subsequently earned a Master of Public Health from the George Washington University. A native of the Pacific Northwest, Matthew currently resides in Washington, DC. Outside of the office, Matthew is an avid runner and enjoys playing bass guitar with his indie rock band.
Matthew Norawong
Advancing mental health in May and beyond
World Mental Health Day: Supporting access to medicines that help loved ones
The role of antidepressants in addressing America’s mental health crisis
The Patient Perspective: Vaccines
New Report: Tackling chronic conditions with preventive treatment
New Report: Vaccines continue to drive improved health outcomes
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
Women’s Health Month: A conversation with Sage
New Report: 1,600 cancer treatments and vaccines in clinical development
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
Support for continued progress is critical for pediatric drug development
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
State policymakers can protect American innovation and help Americans live longer, healthier lives
Recognizing National Glaucoma Awareness Month
ICYMI: Cancer death rate continues to decline due to treatment advances
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
New paper: Addressing the growing crisis of mental health and substance use disorders
Mental Illness Awareness Week – A time for reflection
New Report: Nearly 800 medicines in development to treat chronic conditions
Recognizing National Sickle Cell Awareness Month
Potential gene therapies bring hope to patients with sickle cell disease
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Report: More than 500 medicines in development to treat disorders of the blood
Spotlighting a growing mental health challenge
A conversation with Barry Greene, CEO of Sage Therapeutics
Report: More than 600 medicines in development for diseases affecting women
Guest post: Joining forces to combat the COVID-19 mental health crisis
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
New Report: Nearly 800 new medicines in development to treat rare diseases
Guest post: Continued research and development is critical for ALS patients and families
New report shows more than 260 medicines in development to fight neurodegenerative diseases
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
Reflecting on Mental Health Awareness Month
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
Action needed to preserve the six protected classes
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
Guest Post: Recognizing America’s Veterans
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Guest post: A post-pandemic crisis: The mental toll on America
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
Nearly 400 cell and gene therapies in development to target a broad range of diseases
Nearly 140 medicines in development to treat mental illness
New report shows more than 160 medicines in development for diabetes and related conditions
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
New report shows nearly 300 cell and gene therapies in development
World AIDS Day 2018: Hope for the future
New report shows more than 300 skin disease medicines in development
New report details the setbacks and challenges to Alzheimer’s research
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
A new era in Alzheimer’s innovation
New report shows over 500 medicines in development for neurological disorders
Guest post: Advancing healthy hearts for patients
New report shows 200 medicines in development for heart disease and stroke
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
2017 Research & Hope Awards honor innovators in mental health
Medicare Monday: Strengthening access to vaccines for seniors
Finding cures for incurable diseases
New report portrays flourishing pipeline
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
Opening the conversation around mental health treatment with advocates & industry leaders
More than 240 immuno-oncology treatments in development to fight cancer
Mental health in the New Era of Medicine
Significant progress fighting cancer: Death rate has dropped 25 percent
3 things to know about 2016 drug approvals
New Report More than 160 medicines in development for mental illness
Medicines in Development
Mental Health
New Report More than 160 medicines in development for mental illness
New Report More than 160 medicines in development for mental illness